Lakefront Biotherapeutics NV
Nasdaq LKFT · 2800 Mechelen, Belgium
Works in Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Musculoskeletal · Neurology · Oncology · Ophthalmology · Renal & urogenital · Respiratory · Women's health
Lakefront Biotherapeutics NV is a clinical trial sponsor based in 2800 Mechelen, Belgium, listed as Nasdaq LKFT. It has 1 active clinical trial with 546 planned participants, across 13 therapeutic areas. Since 2021 it has completed 27 trials and stopped 13 early.
Trial track record · since 2021
Financials · Nasdaq LKFT
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 546 planned participants, in Dermatology, Genetic & rare, GI & liver, Hematology and other areas. Since 2021 it has completed 27 trials and stopped 13 early.
Lakefront Biotherapeutics NV is based in 2800 Mechelen, Belgium and is listed as Nasdaq LKFT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Lakefront Biotherapeutics NV; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-07-13.
Approve Suite is not affiliated with Lakefront Biotherapeutics NV.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.